Totaligent Announces Equity-Based Acqui-Hire of Aetherium Medical

Totaligent ( (TGNT) ) has shared an announcement.

On February 11, 2026, Totaligent, Inc. signed a binding letter of intent with Aetherium Medical for an acqui-hire transaction in which Totaligent would acquire Aetherium’s team, business plan, intellectual property, know-how, contacts, and related assets in exchange for equity rather than cash. The deal structure includes creating a new wholly owned subsidiary, Aetherium Medical LLC, appointing Aetherium CEO Ivan Klarich as its managing director, and issuing restricted preferred stock equal to 10% of Totaligent’s outstanding common equity to Klarich and key team members, subject to performance-based vesting, escrow and repurchase protections, while excluding assumption of liabilities except as expressly agreed.

The parties aim to finalize definitive agreements and close around March 5, 2026, with binding exclusivity, confidentiality, expense, and Delaware-law provisions in place through at least April 5, 2026, while closing remains contingent on due diligence, final documentation and absence of material adverse changes. This structure underscores Totaligent’s strategy of using equity to attract specialized talent and assets, potentially enhancing its capabilities in the medical sector without immediate cash outlays but also diluting existing shareholders by issuing a meaningful equity stake to the incoming Aetherium team.

More about Totaligent

Totaligent, Inc. operates as a corporate parent pursuing growth through strategic acquisitions and acqui-hire transactions rather than cash-intensive deals, using equity issuances and wholly owned subsidiaries to integrate teams, intellectual property, and business plans into its broader platform.

Average Trading Volume: 54,485

Technical Sentiment Signal: Sell

Current Market Cap: $3.66M

Learn more about TGNT stock on TipRanks’ Stock Analysis page.